Astrazeneca (AZN) EBT Margin (2009 - 2026)
Astrazeneca (AZN) recorded quarterly EBT Margin of 5083.12% in Q1 2026, down 88.4% quarter-over-quarter from 43816.67% in Q4 2025, and up 48582.0% on a YoY basis from N/an in Q1 2025.
Astrazeneca (AZN) EBT Margin (2009 - 2026) Analysis & Trends
Astrazeneca's EBT Margin history runs 18 years deep, the most recent figure standing at 5083.12% for Q1 2026.
- In Q1 2026, EBT Margin rose 48582.0% year-over-year to 5083.12%; the TTM figure through Mar 2026 stood at 12660.78% (up 1168463.0% YoY), while the FY2025 annual figure was 21.11%, down 92049.0% from the prior year.
- EBT Margin was 5083.12% for Q1 2026 at Astrazeneca, down from 43816.67% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 59925.0% in Q2 2024 to a low of 204.42% in Q4 2024.
- Historically, EBT Margin has averaged 12498.24% across 5 years, with a median of 4597.3% in 2025.
- The sharpest annual moves came in 2024 and 2025: EBT Margin jumped 5884313 bps in 2024, then tumbled 2083750 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 492.41% in 2022, then tumbled by 34 bps to 323.83% in 2023, then tumbled by 37 bps to 204.42% in 2024, then jumped by 21335 bps to 43816.67% in 2025, then tumbled by 88 bps to 5083.12% in 2026.
- The last three EBT Margin figures came in at 5083.12% (Q1 2026), 43816.67% (Q4 2025), and 29490.91% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 28.10% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 28.20% |
| 10 | Astrazeneca | 72.15 Bn | 64.21 Bn | 12.61 Bn | 5,083.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,083.12% |
| Dec 31, 2025 | 43,816.67% |
| Sep 30, 2025 | 29,490.91% |
| Jun 30, 2025 | 39,087.50% |
| Mar 31, 2025 | 4,597.30% |
| Dec 31, 2024 | 204.42% |
| Sep 30, 2024 | 3,098.31% |
| Jun 30, 2024 | 59,925.00% |
| Mar 31, 2024 | 6,222.22% |
| Dec 31, 2023 | 323.83% |
| Sep 30, 2023 | 1,703.09% |
| Jun 30, 2023 | 1,081.87% |
| Mar 31, 2023 | 8,377.78% |
| Dec 31, 2022 | 492.41% |
| Sep 30, 2022 | 517.98% |
| Jun 30, 2022 | 8,233.33% |
| Mar 31, 2022 | 214.34% |
| Dec 31, 2021 | -123.98% |
| Sep 30, 2021 | -1,600.80% |
| Jun 30, 2021 | 436.57% |